Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: Extraordinary Shareholders' Meeting approves all resolutions

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos Biotechnology AG: Extraordinary Shareholders' Meeting approves
all resolutions

16.03.2015 / 11:12
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd. approves
all resolutions

Schlieren (Zurich), Switzerland, March 16, 2015 - Cytos Biotechnology Ltd
("Cytos" or the "Company"), announced today that its shareholders have
approved all resolutions at today's Extraordinary Shareholders' Meeting.
These resolutions, among other things, consist of an ordinary capital
increase of 77.49 million shares which will be used to exchange the
outstanding convertible bonds into shares once the convertible bond
restructuring proposal becomes final and binding which is expected to be in
the second half of April 2015. After the exchange of the bonds into shares,
a total of around 108 million Cytos shares with a nominal value of CHF 0.03
each will be issued and outstanding.

The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took
place at the Company's headquarters in Schlieren (Zurich), Switzerland. It
was attended by 52 shareholders. 4'757'980 shares or 15.6% of a total of
30,525,276 shares were represented.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=EHEMAXUOQL
Document title: Cytos_EGM_150316

---------------------------------------------------------------------

16.03.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news
archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
333433 16.03.2015
 



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: